Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Sanofi's Sarclisa shows subcutaneous form is as effective as IV in treating multiple myeloma.
Sanofi's Sarclisa, used to treat relapsed multiple myeloma, has shown its subcutaneous form is as effective as the intravenous version in a phase 3 study.
The trial, using the enFuse hands-free delivery system, met its primary goals, suggesting the subcutaneous form offers similar outcomes and potentially better convenience for patients.
Full results will be shared at a future medical conference, and Sanofi plans to submit the subcutaneous form for approval in the US and EU in the first half of 2025.
7 Articles
Sarclisa de Sanofi muestra que la forma subcutánea es tan eficaz como la IV en el tratamiento del mieloma múltiple.